Natriuretic Peptides Regulate the Expression of Tissue Factor and PAI-1 in Endothelial Cells

Summary

In the present study, we demonstrate that brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) interact with angiotensin II (Ang II) in regulative blood coagulation and fibrinolysis by suppressing the expressions of both tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) induced by Ang II. The expressions of TF and PAI-1 mRNA were analyzed by northern blotting methods, and the activities of TF on the surface of rat aortic endothelial cells (RAECs) and PAI-1 in the culture media were respectively measured by chromogenic assay.

Both BNP and CNP suppressed the expressions of TF and PAI-1 mRNA induced by Ang II in a time- and concentration-dependent manner via cGMP cascade, which suppressions were accompanied by respective decrease in activities of TF and PAI-1. However, neither the expression of tissue factor pathway inhibitor (TFPI) nor tissue-type plasminogen activator (TPA) mRNA was affected by the treatment of BNP and CNP.

Key words

BNP - CNP - Ang II - coagulation - fibrinolysis

• References

• 1 Kangawa K, Matsuo H. Purification and complete amino acid sequence of α-human atrial natriuretic polypepetide (α-hANP). Bioehem Biophys Res Commun 1984; 118: 131-9.
• 2 DeBold AJ. Atrial natriuretic factor: A hormone produced by the heart. Science 1985; 230: 767-80.
• 3 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
• 4 Nakao K, Itoh H, Kambayashi Y, Hosoda K, Saito Y, Yamada T, Mukoyama M, Arai H, Shirakami G, Suga S, Jougasaki M, Ogawa Y, Inouye K, Imura H. Rat brain natriuretic peptide. Isolation from rat heart and tissue distribution. Hypertension 1990; 15: 774-8.
• 5 Grantham JA, John C, Burnett Jr BNP. Increasing Importance in the Pathophysiology and Diagnosis of Congestive Heart Failure. Circulation 1997; 96: 388-90.
• 6 Itoh H, Nakao K. Natriuretic peptide system. Nippon Rinsho 1997; 55: 1923-36.
• 7 Itoh H, Nakao K. Antagonism between the vascular renin-angiotensin and natriuretic peptide systems in vascular remodelling. Blood Press Suppl 1994; 5: 49-53.
• 8 Burnett Jr Hu PC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science Wash 1986; DC231: 1145-7.
• 9 Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, Kambayashi Y, Inouye K, Imura H. Brain natriuretic peptide (BNP) as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.
• 10 Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
• 11 Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168 (02) 863-70.
• 12 Wei CM, Aarhus LL, Miller VM, Burnett Jr JC. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol 1993; 264 (01) (Suppl. 02) H71-3.
• 13 Stingo AJ, Clavell AL, Aarhus LL, Burnett Jr JC. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992; 262 (01) (Suppl. 02) H308-12.
• 14 Furuya M, Aisaka K, Miyazaki T, Honbou N, Kawashima K, Ohno T, Tanaka S, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun 1993; 193 (01) 248-53.
• 15 Porter JG, Catalano R, McEnroe G, Lewicki JA, Protter AA. C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. Am J Physiol 1992; 263 (05) (Suppl. 01) C1001-6.
• 16 Clavell AL, Stingo AJ, Wei CM, Heublein DM, Burnett Jr JC. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 1993; 264 (02) (Suppl. 02) R290-5.
• 17 Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, Kasahara T, Sugano T, Yoshizumi M, Sawada S, Nakagawa M. Angiotensin II increases plasuminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasuminogen activator or tissue factor pathway inhibitor in cultured rat endothelial cells. Thromb Haemost 1997; 77: 1189-95.
• 18 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
• 19 Yoshizumi M, Tsuji H, Nishimura H, Kasahara T, Sugano T, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, Yamada K, Yoneda M, Sawada S, Nakagawa M. Atrial Natriuretic Peptide Inhibits the Expression of Tissue Factor and Plasminogen Activator Inhibitor 1 Induced by Angiotensin II in Cultured Rat Aortic Endothelial Cells. Thromb Haemost 1998; 79: 631-4.
• 20 McGuire PG, Orkin RW. Methods in laboratory investigation Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab Invest 1987; 57: 94-105.
• 21 Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 1984; 99: 2034-40.
• 22 Thomas PS. Hybridization of denatured RNA and small DNA fragments to nitrocellulose. Proc Natl Acad Sci USA 1983; 77: 5201-5.
• 23 Rosenfield CL. Rattus norvegicus Sprague-Dawley tissue factor protein mRNA, complete cds. GenBank accession. 1994: U07619.
• 24 Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73: 459-68.
• 25 Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem 1992; 111: 681-7.
• 26 Ny T, Leonardsson G, Hsueh AJW. Cloning and characterization of cDNA for rat tissue-type plasminogen activator. DNA 1988; 7: 671-7.
• 27 Tso JY, Sun XH, Kao TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucleic Acid Res 1985; 13: 2485-502.
• 28 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am Pathol 1989; 134: 1087-97.
• 29 Butt E, van Bemmelen M, Fischer L, Walter U, Jastorff B. Inhibition of cGMP-dependent protein kinase by (Rp)-guanosine 3’,5’-monophosphorothioates. FEBS Lett 1990; 263 (01) 47-50.
• 30 Needleman P, Adams SP, Cole BR, Currie MG, Geller DM, Michener ML, Saper CB, Schwartz D, Standaert DG. Atriopeptins as cardiac hormones. Hypertension 1985; Jul-Aug 7 (04) 469-82.
• 31 Nakao K, Morii N, Itoh H, Yamada T, Shiono S, Sugawara A, Saito Y, Mukoyama M, Arai H, Sakamoto M. Atrial natriuretic polypeptide in the brain: implication of central cardiovascular control. J Hypertens Suppl 1986; 4 (06) S492-S6.
• 32 Hama N, Itoh H, Suga S, Komatsu Y, Yoshimasa T, Nakao K. A monoclonal antibody to C-type natriuretic peptide – preparation and application to radioimmunoassay and neutralization experiment. J Endocrinol 1994; 141 (03) 473-9.
• 33 Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18 (11) 1771-9.
• 34 Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, Saito Y, Suga S, Jougasaki M, Imura H. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 1991; 69 (02) 491-500.
• 35 Kohno M, Horio T, Yoshiyama M, Takeda T. Accelerated secretion of brain natriuretic peptide from the hypertrophied ventricles in experimental malignant hypertension. Hypertension 1992; 19 (02) 206-11.
• 36 Kohno M, Sambhi MP, Eggena P, Clegg K, Kanayama Y, Takaori K, Takeda T. An accelerated increase of circulating atrial natriuretic polypeptide in salt-loaded spontaneously hypertensive rats. Horm Metab Res 1986; 18 (02) 147-8.
• 37 Yokota N, Aburaya M, Yamamoto Y, Kato J, Kitamura K, Kida O, Eto T, Minamino N, Kangawa K, Matsuo H. Increased plasma brain natriuretic peptide levels in DOCA-salt hypertensive rats: Relation to blood pressure and cardiac concentration. Biochem Biophys Res Commun 1990; 173 (02) 632-8.
• 38 Zimmerman RS, Martinez AJ, MacPhee AA, Barbee RW. Atrial natriuretic factor blocks the presser action of endothelin. J Cardiovasc Pharmacol 1990; 16 (16) 865-70.
• 39 Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3’, 5’-monophosphate. Hypertension 1992; 19 (04) 320-5.
• 40 Kishimoto I, Nakao K, Suga S, Hosoda K, Yoshimasa T, Itoh H, Imura H. Down regulation of C-receptor by natriuretic peptides via ANP-B receptor in vascular smooth muscle cells. Am J Physiol 1993; 265 (04) (Suppl. 02) H1373-H9.
• 41 Chinkers M, Garbers DL, Chang MS, Lowe DC, Chin H, Goeddel DV, Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989; 338: 78-83.
• 42 Chang MS, Lowe DG, Lewis M, Hellmiss R, Chin H, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 1989; 341: 68-72.
• 43 Fuller F, Porter JG, Arfsten AE, Miller J, Schilling JW, Scarborough RM, Lewicki JA, Schenk DB. Atrial natriuretic peptide clearance receptor. J Biol Chem 1988; 263: 9395-9401.
• 44 Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, Goeddel DV. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991; 252: 120-3.
• 45 Suga S, Nakao K, Mukoyama M, Arai H, Hosoda K, Ogawa Y, Imura H. Characterization of natriuretic peptide receptors in cultured cells. Hypertension 1992; 19 (06) (Suppl. 02) 762-5.